Authors: Harris, RJ Kabakoff, B Macchi, FD Shen, FJ Kwong, M Andya, JD Shire, SJ Bjork, N Totpal, K Chen, AB

Citation: Rj. Harris et al., Identification of multiple sources of charge heterogeneity in a recombinant antibody, J CHROMAT B, 752(2), 2001, pp. 233-245

Authors: Lawrence, D Shahrokh, Z Marsters, S Achilles, K Shih, D Mounho, B Hillan, K Totpal, K DeForge, L Schow, P Hooley, J Sherwood, S Pai, R Leung, S Khan, LL Gliniak, B Bussiere, J Smith, CA Strom, SS Kelley, S Fox, JA Thomas, D Ashkenazi, A

Citation: D. Lawrence et al., Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions, NAT MED, 7(4), 2001, pp. 383-385

Authors: Kelley, SK Harris, LA Xie, D Deforge, L Totpal, K Bussiere, J Fox, JA

Citation: Sk. Kelley et al., Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety, J PHARM EXP, 299(1), 2001, pp. 31-38

Authors: Idusogie, EE Wong, PY Presta, LG Gazzano-Santoro, H Totpal, K Ultsch, M Mulkerrin, MG

Citation: Ee. Idusogie et al., Engineered antibodies with increased activity to recruit complement, J IMMUNOL, 166(4), 2001, pp. 2571-2575

Authors: Idusogie, EE Presta, LG Gazzano-Santoro, H Totpal, K Wong, PY Ultsch, M Meng, YG Mulkerrin, MG

Citation: Ee. Idusogie et al., Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc, J IMMUNOL, 164(8), 2000, pp. 4178-4184

Authors: Hymowitz, SG O'Connell, MP Ultsch, MH Hurst, A Totpal, K Ashkenazi, A de Vos, AM Kelley, RF

Citation: Sg. Hymowitz et al., A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL, BIOCHEM, 39(4), 2000, pp. 633-640